Cargando…

Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt

BACKGROUND: The Egyptian government introduced the first directly acting antivirals (DAAs) into Egypt through the government funded National Treatment Program. As yet, there has been no investigation into the effects of these new DAAs therapies on patient reported outcomes (PROs). This study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Youssef, Naglaa F. A., El Kassas, Mohamed, Farag, Amany, Shepherd, Ashley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5251342/ https://www.ncbi.nlm.nih.gov/pubmed/28109264 http://dx.doi.org/10.1186/s12876-017-0581-1

Ejemplares similares

Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study
por: Xu, Xiao-Wei, et al.
Publicado: (2018)

Hepatitis C infection in Egypt: prevalence, impact and management strategies
por: Gomaa, Asmaa, et al.
Publicado: (2017)

Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt
por: Nagaty, Ahmed, et al.
Publicado: (2017)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
por: Hassan, Amro M, et al.
Publicado: (2018)

Forecasted impacts of a sofosbuvir-based national hepatitis C treatment programme on Egypt’s hepatocellular cancer epidemic: simulation of alternatives
por: Ma, Wenkang, et al.
Publicado: (2018)

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients
por: Abdel-Moneim, Adel, et al.
Publicado: (2018)

The Quality of Life of Patients Living with a Urinary Catheter and Its Associated Factors: A Cross-Sectional Study in Egypt
por: Youssef, Naglaa, et al.
Publicado: (2023)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]
Publicado: (2019)

Gender differences in prevalence of hepatitis C virus infection in Egypt: a systematic review and meta-analysis
por: Abdel-Gawad, Muhammad, et al.
Publicado: (2023)

COVID-19 in Egypt: Uncovered figures or a different situation?
por: Medhat, Mohammed A, et al.
Publicado: (2020)

Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir
por: Ismail, Elshahat Ibrahem, et al.
Publicado: (2018)

Potential ecological risk of heavy metals in sediments from the Mediterranean coast, Egypt
por: Soliman, Naglaa Farag, et al.
Publicado: (2015)

Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures
por: Ezzat, Reem, et al.
Publicado: (2021)

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C
por: Saab, Sammy, et al.
Publicado: (2017)

Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?
por: Sarwar, Shahid, et al.
Publicado: (2017)

Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy
por: El-Shabrawi, Mortada HF, et al.
Publicado: (2019)

COVID-19 in Egypt: Through crisis to adaptation; a gastroenterologist’s perspective
por: El Kassas, Mohamed, et al.
Publicado: (2020)

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
por: Joharji, Hala, et al.
Publicado: (2022)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019)

Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats
por: Ibrahim, Mohamed A., et al.
Publicado: (2018)

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
por: de Medeiros, Lucas Pereira Jorge, et al.
Publicado: (2018)

Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt
por: Shoun, Aly Atef, et al.
Publicado: (2022)

End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir
por: Rahman, Attiya S, et al.
Publicado: (2023)

Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities
por: AbouBakr, Othman, et al.
Publicado: (2022)

Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis
por: Shah, Islam, et al.
Publicado: (2021)

Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study
por: Nozaki, Akito, et al.
Publicado: (2021)

Helicobacter pylori infection in patients with inflammatory bowel diseases: a single-centre, prospective, observational study in Egypt
por: Abd El-Wahab, Ekram W., et al.
Publicado: (2022)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Frequent Transient Hepatitis C viremia without Seroconversion among Healthcare Workers in Cairo, Egypt
por: Munier, Aline, et al.
Publicado: (2013)

Cysticercus bovis in cattle slaughtered in North Egypt: Overestimation by the visual inspection method
por: El-Sayad, Mona Hassan, et al.
Publicado: (2021)

Delay in hospital discharge of trauma patients in a University Hospital in Egypt: A prospective observational study
por: El-Abbassy, Islam, et al.
Publicado: (2021)

Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
por: Yada, Masayoshi, et al.
Publicado: (2018)

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
por: Mucenic, Marcos, et al.
Publicado: (2019)

Transcriptional Analysis of TP53 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, Pegylated Interferon, and Ribavirin
por: Chudhary, Hafiza Rida Farooq, et al.
Publicado: (2023)

Prevalence of primary headache disorders in Fayoum Governorate, Egypt
por: El-Sherbiny, Naglaa A., et al.
Publicado: (2015)

Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir
por: Katiyar, Harshita, et al.
Publicado: (2023)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2lkegvu23f71lvgtnsf0b97odo